BlueCrest Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-85,157
Closed -$2.3M – 353
2026
Q2
$2.3M Buy
+85,157
New +$2.34M 0.08% 167

Other funds holding MLYS

BlueCrest Capital Management's MLYS Position: Q3 2026 in Review

BlueCrest Capital Management sold out of Mineralys Therapeutics (MLYS) in Q3 2026, closing a stake of 85,157 shares — an estimated $2.3M sold.

BlueCrest Capital Management first reported a position in MLYS in Q2 2026 and held it in 1 quarter. The position peaked at $2.3M in Q2 2026. 217 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • BlueCrest Capital Management reported no remaining Mineralys Therapeutics position as of Q3 2026 after selling out during the quarter.
  • BlueCrest Capital Management sold 85,157 Mineralys Therapeutics shares in Q3 2026, an estimated $2.3M.
  • BlueCrest Capital Management first reported a position in Mineralys Therapeutics in Q2 2026 and held it in 1 quarter.
  • BlueCrest Capital Management's Mineralys Therapeutics position peaked at $2.3M in Q2 2026.
  • 217 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on BlueCrest Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.